Sanara MedTech (NASDAQ:SMTI – Get Free Report) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its peers? We will compare Sanara MedTech to related businesses based on the strength of its analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.
Earnings & Valuation
This table compares Sanara MedTech and its peers top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Sanara MedTech | $103.12 million | -$37.56 million | -92.43 |
| Sanara MedTech Competitors | $1.87 billion | $136.27 million | 5.73 |
Sanara MedTech’s peers have higher revenue and earnings than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Profitability
This table compares Sanara MedTech and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sanara MedTech | -2.69% | 31.65% | 3.19% |
| Sanara MedTech Competitors | -270.28% | -155.47% | -22.38% |
Institutional and Insider Ownership
8.1% of Sanara MedTech shares are owned by institutional investors. Comparatively, 40.6% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 42.0% of Sanara MedTech shares are owned by insiders. Comparatively, 15.0% of shares of all “Healthcare Equipment & Supplies” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Risk & Volatility
Sanara MedTech has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500. Comparatively, Sanara MedTech’s peers have a beta of 2.58, meaning that their average stock price is 158% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings and target prices for Sanara MedTech and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sanara MedTech | 1 | 4 | 0 | 0 | 1.80 |
| Sanara MedTech Competitors | 4309 | 10596 | 18377 | 837 | 2.46 |
Sanara MedTech presently has a consensus target price of $35.00, indicating a potential upside of 8.19%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 21.38%. Given Sanara MedTech’s peers stronger consensus rating and higher possible upside, analysts plainly believe Sanara MedTech has less favorable growth aspects than its peers.
Summary
Sanara MedTech peers beat Sanara MedTech on 8 of the 13 factors compared.
About Sanara MedTech
Sanara MedTech, Inc. develops, markets and distributes medical products for wound care, surgical tissue repair and related applications. Its offerings are intended for use by healthcare professionals treating acute and chronic wounds and supporting tissue healing. The company’s portfolio includes CellerateRX® collagen-based products and BIAKŌS® antimicrobial products, along with other solutions for wound and surgical care. Sanara sells its products to healthcare providers and through distribution channels.
Receive News & Ratings for Sanara MedTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanara MedTech and related companies with MarketBeat.com's FREE daily email newsletter.
